A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-23)
2019年9月10日 更新者:Forest Laboratories
An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
研究概览
研究类型
介入性
注册 (实际的)
330
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1Y1Z9
- Okanagan Clinical Trials Inc.
-
-
Ontario
-
Toronto、Ontario、加拿大、M6J3S3
- Paediatric Sleep Research Inc
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35213
- Alliance Clinical Research
-
Dothan、Alabama、美国、36303
- Harmonex Neuroscience Research
-
-
Arizona
-
Phoenix、Arizona、美国、85016
- Phoenix Children's Hospital
-
-
Arkansas
-
Little Rock、Arkansas、美国、72211
- Woodland International Research Group, Inc
-
-
California
-
Bellflower、California、美国、90706
- CITrials - Bellflower
-
Costa Mesa、California、美国、92626
- ATP Clinical Research
-
Glendale、California、美国、91206
- Behavioral Research Specialists, LLC
-
San Diego、California、美国、92108
- PCSD - Feighner Research
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Pacific Clinical Research Medical Group
-
-
District of Columbia
-
Washington、District of Columbia、美国、20010
- Children's National Medical Center
-
-
Florida
-
Hialeah、Florida、美国、33012
- Palm Springs Research, LLC
-
Homestead、Florida、美国、33030
- IMIC Inc.
-
Jacksonville、Florida、美国、32256
- Clinical Neuroscience Solutions, Inc.
-
Lauderhill、Florida、美国、33319
- Innovative Clinical Research, Inc.
-
Orlando、Florida、美国、32801
- Clinical Neuroscience Solutions, Inc.
-
-
Georgia
-
Alpharetta、Georgia、美国、30005
- Institute for Advanced Medical Research
-
Atlanta、Georgia、美国、30331
- Atlantic Center for Medical Research
-
Marietta、Georgia、美国、30060
- Northwest Behavioral Research Center
-
-
Illinois
-
Libertyville、Illinois、美国、60048
- Capstone Clinical Research
-
Naperville、Illinois、美国、60563
- Baber Research Group
-
Oak Park、Illinois、美国、60301
- Neuroscience Research Institute Inc.
-
-
Kansas
-
Overland Park、Kansas、美国、66211
- Psychiatric Associates
-
-
Louisiana
-
Lake Charles、Louisiana、美国、70629
- Lake Charles Clinical Trials
-
-
Maryland
-
Baltimore、Maryland、美国、21205
- Hugo W Moser Research Institute at Kennedy Krieger, Inc.
-
Baltimore、Maryland、美国、21208
- Pharmsite Research Inc.
-
Rockville、Maryland、美国、20852
- Neuroscientific Insights
-
-
Massachusetts
-
Springfield、Massachusetts、美国、01199
- Baystate Medical Center
-
Watertown、Massachusetts、美国、02472
- Adams Clinical Trials, LLC
-
-
Missouri
-
Creve Coeur、Missouri、美国、63141
- Millennium Psychiatric Associates
-
Saint Charles、Missouri、美国、63304
- St. Charles Psychiatric Associates - Midwest Research Group
-
-
New York
-
Buffalo、New York、美国、14215
- Erie County Medical Center/State University of New York of Buffalo Affiliate
-
Mount Kisco、New York、美国、10549
- Bioscience Research LLC
-
New York、New York、美国、10022
- Manhattan Behavioral Medicine
-
Rochester、New York、美国、14618
- Finger Lakes Clinical Research
-
Staten Island、New York、美国、10312
- Richmond Behavioral Associates
-
-
Ohio
-
Avon Lake、Ohio、美国、44012
- Haidar Almhana Nieding LLC
-
Canton、Ohio、美国、44718
- Neuro-Behavioral Clinical Research, Inc
-
Cincinnati、Ohio、美国、45219
- University of Cincinnati
-
Cleveland、Ohio、美国、44106
- University Hospitals Cleveland Medical Center, Psychiatr
-
Columbus、Ohio、美国、43210
- Ohio State Univ. Dept of Psychiatry
-
Mason、Ohio、美国、45040
- Professional Psychiatric Services
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73103
- IPS Research Company
-
Oklahoma City、Oklahoma、美国、73116
- Cutting Edge Research Group
-
-
Tennessee
-
Memphis、Tennessee、美国、38119
- Research Strategies of Memphis LLC
-
-
Texas
-
Austin、Texas、美国、78759
- BioBehavioral Research of Austin, PC
-
Houston、Texas、美国、77054
- UT Health Science Center at Houston
-
Houston、Texas、美国、77079
- Houston Endoscopy and Research Ctr
-
Plano、Texas、美国、75093
- Research Across America
-
San Antonio、Texas、美国、78229
- Focus and Balance
-
The Woodlands、Texas、美国、77381
- Family Psychiatry of The Woodlands
-
-
Utah
-
Clinton、Utah、美国、84015
- Ericksen Research and Development
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- UVA Center for Psychopharmacology Research in Youth
-
-
Washington
-
Bellevue、Washington、美国、98007
- Northwest Clinical Research Center
-
Kirkland、Washington、美国、98033
- Core Clinical Research
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
7年 至 17年 (孩子)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Male or Female outpatients betw een 7-17 years of age
- Primary diagnosis of major depressive disorder (MDD)
- Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater
- Clinical Global Impressions-Severity (CGI-S) score of 4 or greater
Exclusion Criteria:
- Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision based diagnosis of an Axis I disorder other than MDD that is the primary focus of treatment (de novo patients only)
- History of suicidal behavior, or requires precaution against suicide
- Not generally healthy medical condition
- Seizure disorder
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Vilazodone
|
Vilazodone tablets, once daily, oral administration
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE)
大体时间:Visit 1 (Week -1) to up to Visit 16 (Week 26)
|
The number of Participants who experienced a treatment emergent adverse events during the 27 week period from screening to the end of the open-label treatment period
|
Visit 1 (Week -1) to up to Visit 16 (Week 26)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in the CDRS-R Total Score
大体时间:Baseline (Week 0) to Week 26
|
The Children's Depression Rating Scale-Revised (CDRS-R) total score ranges from 17 (minimal or no symptoms of depression) to 133 (indicative of depression) is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 to 17 years of age and their caregivers.
The CDRS-R evaluates the presence and severity of symptoms commonly associated with depression in childhood.
|
Baseline (Week 0) to Week 26
|
|
Change From Baseline in the CGI-S Score
大体时间:Baseline (Week 0) to Week 26
|
The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated instrument used to rate the severity of the patient's current state of mental illness compared with the clinician's total experience with patients with major depressive disorder (MDD).
The severity of the patient's MDD was rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating a patient who is among the most extremely ill patients.
|
Baseline (Week 0) to Week 26
|
|
Change From Baseline in Clinical Global Impressions-Improvement (CGI-I)
大体时间:Baseline (Week 0) to Week 26
|
The Clinical Global Impressions-Improvement is a clinician-rated instrument that was used to rate total improvement or worsening of mental illness, regardless of whether the Investigator considered it to be a result of treatment with the investigational product.
The CGI-I was used to rate the patient's improvement on a scale from 1 to 7, with 1 indicating that the patient was very much improved (with a score of 4 indicating no change) and 7 indicating the patient was very much worse.
|
Baseline (Week 0) to Week 26
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Emily McCusker, PhD、Forest Research Institute, Inc., an affiliate of Allergan, plc
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2015年5月2日
初级完成 (实际的)
2018年7月23日
研究完成 (实际的)
2018年7月23日
研究注册日期
首次提交
2015年4月28日
首先提交符合 QC 标准的
2015年5月1日
首次发布 (估计)
2015年5月6日
研究记录更新
最后更新发布 (实际的)
2019年9月11日
上次提交的符合 QC 标准的更新
2019年9月10日
最后验证
2019年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
严重抑郁症的临床试验
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos III完全的
-
Dren BioNovotech Health Holdings Pte. Ltd.招聘中侵袭性 NK 细胞白血病 | 肝脾T细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 单形性趋上皮性肠 T 细胞淋巴瘤 | 原发性皮肤 Gamma-Delta T 细胞淋巴瘤 | LGLL - 大颗粒淋巴细胞白血病 | 系统性 EBV1 T 细胞淋巴瘤,如果 CD8 阳性 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | 结外 NK/T 细胞淋巴瘤,鼻型 | 原发性皮肤CD8+侵略性表皮T细胞淋巴瘤 | 细胞毒性PTCL-NOS(CD8+或CD56+和细胞毒性标记) | 皮肤PTCL-NOS(CD8+或CD56+和细胞毒性标记)美国, 澳大利亚, 台湾, 法国, 西班牙, 意大利, 香港, 德国, 韩国
-
Memorial Sloan Kettering Cancer Center招聘中蕈样肉芽肿 | 塞扎里综合症 | 血管免疫母细胞性T细胞淋巴瘤 | 肝脾T细胞淋巴瘤 | 间变性大细胞淋巴瘤,ALK 阳性 | 结外 NK/T 细胞淋巴瘤,鼻型 | T细胞淋巴瘤 | 未特指的外周 T 细胞淋巴瘤 | 原发性皮肤间变性大细胞淋巴瘤 | 皮下脂膜炎样 T 细胞淋巴瘤 | 肠病相关的T细胞淋巴瘤 | 间变性大细胞淋巴瘤,ALK 阴性 | 单形性趋上皮性肠 T 细胞淋巴瘤 | T 细胞幼淋巴细胞白血病 | T 细胞大颗粒淋巴细胞白血病 | 原发性皮肤 CD8 阳性侵袭性嗜表皮 T 细胞淋巴瘤 | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | NK细胞淋巴瘤 | 侵袭性 NK 细胞白血病 | 成人 T 细胞白血病/淋巴瘤 及其他条件美国